ARTICLE | Clinical News
AFN-1252: Phase I started
April 26, 2010 7:00 AM UTC
Affinium began a double-blind, placebo-controlled, single ascending-dose, U.S. Phase I trial to evaluate 100-800 mg oral AFN-1252 in 64 volunteers. ...
Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
Affinium began a double-blind, placebo-controlled, single ascending-dose, U.S. Phase I trial to evaluate 100-800 mg oral AFN-1252 in 64 volunteers. ...